CUDC-101
CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. It has been shown that CUDC-101 is able to effectively suppress the progression of a broad range of tumor types in both in vitro and in vivo xenograft models, including lapatinib- and erlotinib-resistant cancer cell lines. Mechanistic studies provide the evidence that CUDC-101 not only directly inhibits both EGFR and HER2 signaling but also indirectly attenuates the survival signaling pathways Akt, HER3, and MET.
Reference
Cheng-Jung Lai, Rudi Bao, Xu Tao, Jing Wang, Ruzanna Atoyan, Hui Qu, Da-Gong Wang, Ling Yin, Maria Samson, Jeffrey Forrester, Brian Zifcak, Guang-Xin Xu, Steven DellaRocca, Hai-Xiao Zhai, Xiong Cai, William E. Munger, Mitchell Keegan, Carmen V. Pepicelli, and Changgeng Qian. CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity. Cancer Res May 1, 2010 70; 3647.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 434.49 |
| Cas No. | 1012054-59-9 |
| Formula | C24H26N4O4 |
| Synonyms | CUDC101, CUDC 101 |
| Solubility | ≥21.7 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| Chemical Name | 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide |
| SDF | Download SDF |
| Canonical SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment: [1] | |
|
Cell lines |
MDA-MB-231 cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
1 µM, 16h. |
|
Applications |
MDA-MB-231 human breast carcinoma cells showed that HGF- and EGF-induced migration was significantly reduced by 1 µM CUDC-101. The inhibition of migration and invasion was not a secondary effect of cell death or growth inhibition, as no significant decrease in cell viability under all conditions tested has been detected. |
| Animal experiment : [2] | |
|
Animal models |
four-to 6-week-old female athymic mice (nude nu/nu CD-1) bearing human HepG2 liver cancer cell xenografts |
|
Dosage form |
After tumors reached an average of 281 mm3 in size, mice were orally treated with CUDC-101 at a daily dose of 120 mg/kg. |
|
Applications |
CUDC-101 induced 30% tumor regression. One of the treated mice displayed complete tumor regression at the end of the dosing cycle, an effect that lasted for at least 6 months after treatment. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Wang J, Pursell N W, Samson M E S, et al. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Molecular cancer therapeutics, 2013, 12(6): 925-936. [2] Lai C J, Bao R, Tao X U, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer research, 2010, 70(9): 3647-3656. |
|
| Description | CUDC-101 is a potent inhibitor of HDAC, EGFR and HER2 with IC50 values of 4.4 nM, 2.4 nM, and 15.7 nM, respectively. | |||||
| Targets | EGFR | HDAC | HDAC1 | HDAC6 | HDAC3 | HDAC5 |
| IC50 | 2.4 nM | 4.4 nM | 4.5 nM | 5.1 nM | 9.1 nM | 11.4 nM |
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
